All In Biotech

Drug Trial Radar · NCT05774951

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 4,300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

4,300

Planned (sponsor's estimate)

Start

Mar 31, 2023

Primary completion

Apr 20, 2027

Study completion May 29, 2036

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

Conditions

  • Breast Cancer, Early Breast Cancer

Interventions

  • CamizestrantDrug

    Camizestrant. Experimental. Administered orally

  • TamoxifenDrug

    Tamoxifen. Comparator. Administered per local approved label

  • AnastrozoleDrug

    Anastrozole. Comparator. Administered per local approved label

  • LetrozoleDrug

    Letrozole. Comparator. Administered per local approved label

  • ExemestaneDrug

    Exemestane. Comparator. Administered per local approved label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive breast cancer-free survival (IBCFS)Time frame: Up to 10 years

Locations

709 sites in 39 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Active not recruiting

  • Research Site

    Dothan, Alabama · Active not recruiting

  • Research Site

    Anchorage, Alaska · Active not recruiting

  • Research Site

    Chandler, Arizona · Active not recruiting

  • Research Site

    Hot Springs, Arkansas · Active not recruiting

  • Research Site

    Anaheim, California · Active not recruiting

  • Research Site

    Beverly Hills, California · Active not recruiting

  • Research Site

    Concord, California · Active not recruiting

  • Research Site

    Corona, California · Active not recruiting

  • Research Site

    Fountain Valley, California · Active not recruiting

  • Research Site

    Greenbrae, California · Active not recruiting

  • Research Site

    Los Alamitos, California · Active not recruiting

  • Research Site

    Palo Alto, California · Active not recruiting

  • Research Site

    San Diego, California · Active not recruiting

  • Research Site

    San Diego, California · Active not recruiting

  • Research Site

    Whittier, California · Active not recruiting

  • Research Site

    Aurora, Colorado · Withdrawn

  • Research Site

    Hartford, Connecticut · Active not recruiting

  • Research Site

    Fort Myers, Florida · Active not recruiting

  • Research Site

    Gainesville, Florida · Active not recruiting

  • Research Site

    Miami Beach, Florida · Active not recruiting

  • Research Site

    Orlando, Florida · Active not recruiting

  • Research Site

    Plantation, Florida · Active not recruiting

  • Research Site

    Port Saint Lucie, Florida · Active not recruiting

  • Research Site

    Saint Augustine, Florida · Active not recruiting

  • Research Site

    St. Petersburg, Florida · Active not recruiting

  • Research Site

    St. Petersburg, Florida · Active not recruiting

  • Research Site

    Tallahassee, Florida · Active not recruiting

  • Research Site

    West Palm Beach, Florida · Active not recruiting

  • Research Site

    Winter Haven, Florida · Active not recruiting

  • Research Site

    Atlanta, Georgia · Active not recruiting

  • Research Site

    Atlanta, Georgia · Active not recruiting

  • Research Site

    Columbus, Georgia · Active not recruiting

  • Research Site

    Honolulu, Hawaii · Withdrawn

  • Research Site

    Chicago, Illinois · Withdrawn

  • Research Site

    Chicago, Illinois · Active not recruiting

  • Research Site

    Decatur, Illinois · Active not recruiting

  • Research Site

    Elmhurst, Illinois · Active not recruiting

  • Research Site

    Hinsdale, Illinois · Active not recruiting

  • Research Site

    Park Ridge, Illinois · Terminated

Showing 40 of 709 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.